Tissue Dynamics and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announce a strategic collaboration to jointly develop a chronic cardiac fibrosis research platform focused on human disease models.

This collaboration aims to accelerate the development of novel therapies based on Aramchol (Galmed's core candidate drug). The partnership will combine Tissue Dynamics' expertise in dynamic monitoring of human tissues with Galmed's experience in the research and development of metabolic disease treatments, focusing on the field of cardiac fibrosis, a chronic disease affecting millions of patients worldwide. By establishing experimental platforms that more closely replicate human pathophysiological characteristics, both parties aim to enhance drug research and development efficiency and provide more precise treatment options for cardiovascular disease patients.